Table 1a.
Population characteristics for prophylaxis treatment.
| Variable | Population (N= 14) |
|---|---|
|
| |
| Median follow-up, months, (range) | 14 (12–47) |
|
| |
| Patient median age (range) | 45 (20–65) |
|
| |
| Disease, n (%) | |
| AL | 12 (86%) |
| Lymphoma or MM | 2 (14%) |
|
| |
| Disease status, n (%) | |
| CR1 | 8 (57%) |
| CR>1 | 2 (14%) |
| Advanced | 4 (29%) |
|
| |
| Donor, n (%) | |
| MRD | 2 (14%) |
| MUD | 7 (50%) |
| Haploidentical | 3 (22%) |
| CBU | 2 (14%) |
|
| |
| Recipient CMV status, n (%) | |
| Positive | 12 (86%) |
| Negative | 2 (14%) |
|
| |
| Donor CMV status, n (%) | |
| Positive | 2 (14%) |
| Negative | 12 (86%) |
|
| |
| Recipient/donor CMV status, n (%) | |
| Neg/neg | 1 (7%) |
| Neg/pos | 1 (7%) |
| Pos/neg | 11 (79%) |
| Pos/pos | 1 (7%) |
|
| |
| Conditioning intensity, n (%) | |
| RIC | 0 |
| MAC | 14 (100%) |
|
| |
| Stem cell source, n (%) | |
| PB | 12 (86%) |
| BM | 0 |
| CBU | 2 (14%) |
|
| |
| Main GvHD-prophylaxis platform, n (%) | |
| T-repleted, ATG-based | 4 (29%) |
| T-repleted, PTCy-based | 1 (7%) |
| T-repleted, other | 9 (64%) |
| Details: | |
| ATG – CSA+MTX±MMF | 4 (29%) |
| PTCy – CSA+MMF | 1 (7%) |
| Siroli+MMF | 9 (64%) |